clinical-pathology-epidemiology-2019-keynote

6 / 6

Journal of Infectious Diseases and Treatment
ISSN: 2472-1093 Clinical Pathology & Epidemiology 2019 Page 43
Clinical Pathology and Epidemiology
February 27-28, 2019 | Prague, Czech Republic
7th Euroscicon Conference on
Background: Pneumococcal infection (PI) is one of the most important causes of recurrent
respiratory infections. The 23-valent pneumococcal polysaccharide vaccine (PPV23) has been
demonstrated cost-effective in reducing the burden of PI. We report the clinical and serological
response of patients diagnosed with recurrent respiratory tract infections, after immunization with
a single dose of the PPV23.
Methods: Fourteen subjects from the infectious diseases and immunodeficiencies ambulatory of
a public tertiary hospital, São Paulo state, Brazil, who were up to 10 years of age, had received
pneumococcal conjugated vaccine 10 (PCV-10), and were unable to develop an adequate
response (G1); and >10 years of age that had not received PCV-10 (G2). For G1, blood samples
were collected immediately prior to vaccination, and about 30-60 d post vaccination for the whole
group. A specific IgG concentration ≥1.3 g/mL, at least in 60% of serotypes was considered a
protective response. Clinical and serological response to PPV23 was assessed at approximately 1,
3, 6 months and 1 year after immunization.
Results: Concerning gender, 24 (60%) were male and 16 (40%) were female (p>0.05). For G1, the
mean age was 6.90±0.41 (95% CI=5.98-7.83) and 35.60±4.9 (25.09-46.11) for G2. Fourteen of
these patients had received PCV10 and after immunization with the PPV23, 15 (100%) obtained
a serological adequate response. For G2, 25 (62.5%) were vaccinated and 9 (36.0%) developed a
serological adequate response. Positive clinical response was obtained in 24 (60.0%) patients; 8
(20.0%) had a partial clinical response and 8 (20%) were unable to develop an adequate response.
Twenty patients (50%) were diagnosed with common variable immunodeficiencies (CVID), or
secondary panhypogammaglobulinemia, and of these, one (2.5%) developed a normal response
to PPV23.
Conclusion: Polysaccharide vaccine was effective in protecting immunized patients against
respiratory infections, although in patients with CVID, an inadequate antibody response was found.
The role of a single dose of pneumo-23
vaccine in preventing recurrent
respiratory tract infection in patients
of tertiary public infectious diseases/
immunodeficiencies ambulatory
Luiz Euribel Prestes Carneiro1, Giovana Pelizari1, Denise
Helena Boton Pereira1, Livia Souza Primo1 and Dewton de
Moraes Vasconcelos2
1Oeste Paulista University, Brazil
2Hospital das Clınicas da Faculdade de Medicina da Universidade de Sao Paulo, Brazil
Biography
Luiz Euribel Prestes Carneiro has completed his
PhD in Immunology at University of Sao Paulo,
Brazil. Currently, he is a Professor in the Emergency
Department and Coordinator of the Master in Health
Sciences (Medicine II) at Oeste Paulista University,
and in the Infectious Diseases Department at the
State Maternity of Presidente Prudente. He has 25
articles published in PubMed, belongs to the Editorial
Board of two Brazilian journals, five international
scientific journals and acts as Reviewer for 28
international scientific journals. He has experience
in the area of Immunology and Infectious Diseases,
with emphasis on Human Immunodeficiency Virus,
Viral Hepatitis, Visceral leishmaniasis and Primary
Immunodeficiencies.
Luiz Euribel Prestes Carneiro et al., J Infec Dis Treat 2019, Volume: 5
DOI: 10.21767/2472-1093-C1-007